Myeloma Canada is thrilled to announce that as of March 14 2019, daratumumab (Darzalex) is now covered for Ontario myeloma patients who are experiencing one or more relapses.
A huge thank you to Myeloma Canada’s Ontario Advocacy Committee, and everyone who got involved in advocating for access to this important treatment. Together, we are stronger in making myeloma matter.
Daratumumab is now funded through the Cancer Care Ontario New Drug Funding Program for patients with good performance status who have received at least one prior therapy, either in combination with bortezomib (Velcade) and dexamethasone or in combination with lenalidomide (Revlimid) and dexamethasone.
Ontario myeloma patients now have access to another vital therapy proven to provide better patient outcomes and improve quality of life.